Literature DB >> 22225999

Approaches to data analyses of clinical trials.

Curt D Furberg1, Lawrence M Friedman.   

Abstract

There are two types of data analyses of randomized clinical trials (RCTs). The primary analyses are pre-specified in the protocol and the findings form the basis for recommendations and clinical decisions. They typically adhere to the intention-to-treat principle. Secondary analyses are supplemental and of various sorts. Although some may be pre-specified, many are not. We encourage the use of the rich sources of data from large RCTs for these secondary purposes. Depending on the kinds of secondary analyses, whether they are pre-specified, and whether intention-to-treat analysis is used, the results range from being quite conclusive to being hypothesis generating. In this article we answer four questions related to secondary analysis with emphasis on sharing of data primarily from NIH-sponsored trials: Who has access to this information? What questions can be asked? What are the requirements? What are the common challenges?
Copyright © 2012. Published by Elsevier Inc.

Mesh:

Year:  2012        PMID: 22225999     DOI: 10.1016/j.pcad.2011.07.002

Source DB:  PubMed          Journal:  Prog Cardiovasc Dis        ISSN: 0033-0620            Impact factor:   8.194


  9 in total

1.  Inability of Turbidimetry Method in Detecting Glycated Hemoglobin to Select Diabetes Mellitus Patients According to Their Concentrations of Blood Glucose Levels.

Authors:  Alessandra M Abdallah; Beatriz C A Alves; Flávia S Gehrke; Aleksandra V L Sant' Ana; Ligia A Azzalis; Virginia B C Junqueira; Fernando Adami; Edimar C Pereira; Fernando L A Fonseca
Journal:  J Clin Lab Anal       Date:  2014-08-17       Impact factor: 2.352

Review 2.  Tutorial: best practices and considerations for mass-spectrometry-based protein biomarker discovery and validation.

Authors:  Ernesto S Nakayasu; Marina Gritsenko; Paul D Piehowski; Yuqian Gao; Daniel J Orton; Athena A Schepmoes; Thomas L Fillmore; Brigitte I Frohnert; Marian Rewers; Jeffrey P Krischer; Charles Ansong; Astrid M Suchy-Dicey; Carmella Evans-Molina; Wei-Jun Qian; Bobbie-Jo M Webb-Robertson; Thomas O Metz
Journal:  Nat Protoc       Date:  2021-07-09       Impact factor: 17.021

3.  The influence of a consumer-wearable activity tracker on sedentary time and prolonged sedentary bouts: secondary analysis of a randomized controlled trial.

Authors:  Robert A Sloan; Youngdeok Kim; Aarti Sahasranaman; Falk Müller-Riemenschneider; Stuart J H Biddle; Eric A Finkelstein
Journal:  BMC Res Notes       Date:  2018-03-22

Review 4.  Nanopharmaceutics: Part I-Clinical Trials Legislation and Good Manufacturing Practices (GMP) of Nanotherapeutics in the EU.

Authors:  Eliana B Souto; Gabriela F Silva; João Dias-Ferreira; Aleksandra Zielinska; Fátima Ventura; Alessandra Durazzo; Massimo Lucarini; Ettore Novellino; Antonello Santini
Journal:  Pharmaceutics       Date:  2020-02-11       Impact factor: 6.321

5.  Utility of the Autism Diagnostic Observation Schedule and the Brief Observation of Social and Communication Change for Measuring Outcomes for a Parent-Mediated Early Autism Intervention.

Authors:  Sophie Carruthers; Tony Charman; Nicole El Hawi; Young Ah Kim; Rachel Randle; Catherine Lord; Andrew Pickles
Journal:  Autism Res       Date:  2020-12-04       Impact factor: 5.216

6.  Lack of Association between Postoperative Pancreatitis and Other Postoperative Complications Following Pancreaticoduodenectomy.

Authors:  Daegwang Yoo; Seo Young Park; Dae Wook Hwang; Jae Hoon Lee; Ki Byung Song; Woohyung Lee; Yejong Park; Eunsung Jun; Song Cheol Kim
Journal:  J Clin Med       Date:  2021-03-11       Impact factor: 4.241

7.  Evidence-based new service package vs. routine service package for smoking cessation to prevent high risk patients from cardiovascular diseases (CVD): study protocol for randomized controlled trial.

Authors:  Myo Nyein Aung; Motoyuki Yuasa; Thaworn Lorga; Saiyud Moolphate; Hiroshi Fukuda; Tsutomu Kitajima; Hirohide Yokokawa; Kazuo Minematsu; Susumu Tanimura; Yoshimune Hiratsuka; Koichi Ono; Prissana Naunboonruang; Payom Thinuan; Sachio Kawai; Yaoyanee Suya; Somboon Chumvicharana; Eiji Marui
Journal:  Trials       Date:  2013-12-05       Impact factor: 2.279

Review 8.  A Comprehensive Review on MAPK: A Promising Therapeutic Target in Cancer.

Authors:  Cornelia Braicu; Mihail Buse; Constantin Busuioc; Rares Drula; Diana Gulei; Lajos Raduly; Alexandru Rusu; Alexandru Irimie; Atanas G Atanasov; Ondrej Slaby; Calin Ionescu; Ioana Berindan-Neagoe
Journal:  Cancers (Basel)       Date:  2019-10-22       Impact factor: 6.639

9.  Longitudinal study of inflammatory, behavioral, clinical, and psychosocial risk factors for chemotherapy-induced peripheral neuropathy.

Authors:  Ian R Kleckner; Todd A Jusko; Eva Culakova; Kaitlin Chung; Amber S Kleckner; Matthew Asare; Julia E Inglis; Kah Poh Loh; Luke J Peppone; Jessica Miller; Marianne Melnik; Samer Kasbari; Deborah Ossip; Karen M Mustian
Journal:  Breast Cancer Res Treat       Date:  2021-06-30       Impact factor: 4.624

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.